Avenge announced the closing of a $45 million Series A financing co-led by Perceptive Xontogeny Venture Fund and CAM Capital, with participation from sole seed investor Longitude Capital and new investors Rock Springs Capital, and Pappas Capital.

Avenge Bio is an oncology-focused biotechnology company developing transformative cell-based immunotherapeutic products for the treatment of intractable solid tumors by incorporating its LOCOcyte platform. The LOCOcyte platform leverages proprietary engineered cells delivered to the local tumor environment that generate high concentrations of immune effector molecules in proximity to the tumor.